ArticleBMC medical imaging2025
MRI-based model for individualized prediction of skull bone destruction and EBV DNA-related risk stratification in nasopharyngeal carcinoma patients.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to develop an MRI-based radiomics score (MRscore) derived from CE-T1WI and T2WI sequences for predicting skull bone destruction in patients with nasopharyngeal carcinoma (NPC), and to evaluate its performance across EBV DNA and sex subgroups.
methodsThis retrospective study included 175 patients with histologically confirmed NPC who underwent baseline MRI. Radiomic features were extracted from CE-T1WI and T2WI sequences. Least absolute shrinkage and selection operator (LASSO) logistic regression was used for feature selection and MRscore construction. Receiver operating characteristic (ROC) analysis was used to assess model performance, and subgroup analyses were conducted based on plasma EBV DNA levels and sex. Cutoff stability was evaluated using bootstrap resampling.
resultsNine radiomic features were selected to construct the MRscore. The model showed good predictive performance for skull bone destruction with an AUC of 0.844. Subgroup analysis demonstrated consistent performance in both EBV DNA-high (AUC = 0.880) and low (AUC = 0.810) groups, as well as in male (AUC = 0.853) and female (AUC = 0.812) patients. The MRscore cutoff value remained stable across bootstrapped samples, and precision–recall curves supported its robustness under class imbalance.
conclusionsThe MRscore provides a non-invasive, individualized tool for predicting skull bone destruction in NPC, demonstrating stable performance across EBV DNA and sex subgroups. These results support its potential role in risk stratification and personalized treatment planning. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.